ArticleCytoJournal2025
The anti-cancer role of tumor protein p53-inducible nuclear protein 2/nuclear factor-kB/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 pathway in spinal cord glioma.
Article in CytoJournal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The function of tumor protein p53-inducible nuclear protein 2 (TP53INP2) in numerous cancers has been elucidated, but its role across the development of spinal cord glioma (SCG) remains largely unexplored. This study aims to explore the anti-cancer effect of TP53INP2/nuclear factor-kappa B (NF-kB)/nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway in SCG. Material and Methods: Quantitative real-time polymerase chain reaction was employed to determine TP53INP2 messenger RNA expression Results: High expression of TP53INP2 was observed in glioma cells. TP53INP2 depletion significantly inhibited tumor growth, metastasis, EMT, and oxidative stress and increased the apoptosis rate and number of immune cells. The silenced TP53INP2 hampered the activation of NF-kB and promoted the activation of the Nrf2/HO-1 pathway. Conclusion: This work highlights the therapeutic potential of TP53INP2/NF-kB/Nrf2/HO-1 axis in SCG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.